Novel Use of a Nicotinic Receptor Agonist 156
AssigneeAstraZeneca AB
InventorsSarah Maria Valentine Brockbank, Maurice Ronald Charles Needham, Peter Newham, Timothy Martin Piser, Jeffrey Scott Smith
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel method of treatment or prophylaxis of osteoarthritis, which comprises administering to a patient in need thereof a therapeutically effective amount of an alpha 7 nicotinic AcetylCholine receptor agonist of Formula (I), or a pharmaceutically acceptable salt thereof:
Claims18
A method of treatment or prophylaxis of osteoarthritis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
A method of treatment or prophylaxis of osteoarthritis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (IA), or a pharmaceutically acceptable salt thereof:
A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically-acceptable salt thereof:
- and a pharmaceutically acceptable carrier or diluent, for use in the treatment or prophylaxis of osteoarthritis.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (IA), or a pharmaceutically-acceptable salt thereof:
- and a pharmaceutically acceptable carrier or diluent, for use in the treatment or prophylaxis of osteoarthritis.
A pharmaceutical composition comprising
- 0.0001 to 10 mg of a compound of Formula (I), or a pharmaceutically-acceptable salt thereof:
- in combination with a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition comprising 0.0001 to 10 mg of a compound of Formula (IA), or a pharmaceutically-acceptable salt thereof:
- in combination with a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.